Having trouble accessing articles? Reset your cache.

Merck KGaA, Symphogen in cancer deal

Symphogen A/S (Copenhagen, Denmark) granted Merck KGaA (Xetra:MRK) exclusive, worldwide rights to develop and commercialize cancer product Sym004.

Read the full 181 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE